Thus, it seems reasonable to predict that PTP1B inhibitors—which restore insulin sensitivity in T2D models (Malamas et al., 2000; Zinker et al., 2002; Gum et al., 2003; Panzhinskiy et al., 2013; Tamrakar et al., 2014)—may rescue neurons from defective insulin signaling in AD. This evidence concerns the gene PTPN1 and Alzheimer disease.